<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37680987</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2162-2531</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><PubDate><Year>2023</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Molecular therapy. Nucleic acids</Title><ISOAbbreviation>Mol Ther Nucleic Acids</ISOAbbreviation></Journal><ArticleTitle>The current landscape of long COVID clinical trials: NIH's RECOVER to Stanford Medicine's STOP-PASC initiative.</ArticleTitle><Pagination><StartPage>887</StartPage><EndPage>889</EndPage><MedlinePgn>887-889</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtn.2023.08.016</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chakraborty</LastName><ForeName>Chiranjib</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal 700126, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharya</LastName><ForeName>Manojit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Zoology, Fakir Mohan University, Vyasa Vihar, Balasore, Odisha 756020, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Nucleic Acids</MedlineTA><NlmUniqueID>101581621</NlmUniqueID><ISSNLinking>2162-2531</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>8</Day><Hour>4</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37680987</ArticleId><ArticleId IdType="pmc">PMC10481149</ArticleId><ArticleId IdType="doi">10.1016/j.omtn.2023.08.016</ArticleId><ArticleId IdType="pii">S2162-2531(23)00228-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kozlov M. NIH launches trials for long COVID treatments: what scientists think. Nature. 2023 doi: 10.1038/d41586-023-02472-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-02472-1</ArticleId><ArticleId IdType="pubmed">37528203</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lancet Infectious D. Where are the long COVID trials? Lancet Infect. Dis. 2023;23:879.</Citation><ArticleIdList><ArticleId IdType="pubmed">37507151</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxlovid for treatment of long covid. 2023. https://stanfordhealthcare.org/trials/p/NCT05576662.html</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla H., Peluso M.J., Rodgers K., Aberg J.A., Patterson T.F., Tamburro R., Baizer L., Goldman J.D., Rouphael N., Deitchman A., et al. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front. Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10034329</ArticleId><ArticleId IdType="pubmed">36969241</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) S, of IGNSaRC, (RCGP) GP  . 2022. COVID-19 rapid guideline: Managing the long-term effects of COVID-19.https://www.nice.org.uk/guidance/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  National center for immunization and respiratory diseases (NCIRD) DoVD. long COVID or post-COVID conditions. 2022. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>